Cross-Sector entity
Every one of those 1 sits in a single category, pharma. Of the tracked stories, 1 of 1 also mention Bank of America Corp DE, the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Cross-Sector story that mention Spyglass Pharma, Inc., all published on August 10, 2026.
1 verified story tracked
Last mentioned: Aug 10, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, pharma. Of the tracked stories, 1 of 1 also mention Bank of America Corp DE, the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Cross-Sector story that mention Spyglass Pharma, Inc., all published on August 10, 2026.
Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Spyglass Pharma, Inc.. Shared-story counts are live from our verified record — not editorial picks.
Spyglass Pharma's stock plunges to a new 52-week low of $17.56 despite a consensus 'Moderate Buy' rating and an average analyst target of $45. For biotech investors, the 156% upside potential must be weighed against a recent earnings miss and a downgrade to sell, raising questions about near-term pipeline catalysts.
Source: tickerreport.com · dailypolitical.com
